Furmonertinib is currently being evaluated in combination trials for patients with EGFR mutation-positive NSCLC (ClinicalTrials.gov Identifier: NCT05430802, NCT05503667, NCT05334277, NCT04895930, and NCT03787992). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.